You are here

An Investigation of Effectiveness and Safety of Varenicline Tartrate in Helping People Quit Smoking

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Shenyang, Liaoning, 110016 China
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Smoking Cessation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Current cigarette smokers between the ages of 18 and 75 years, who are motivated to
stop smoking

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients currently suffering from depression, or have been diagnosed with depression
in the last 12 months, or subjects with past or present history of psychosis, panic
disorder, or bipolar disorder

- Any subject with known severe chronic obstructive pulmonary disease (COPD)

NCT00371813
Pfizer
Completed
An Investigation of Effectiveness and Safety of Varenicline Tartrate in Helping People Quit Smoking

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Smoking Cessation
NCT01312909
All Genders
12+
Years
Multiple Sites
Smoking Cessation
NCT00150241
All Genders
18+
Years
Multiple Sites
Smoking Cessation
NCT00143299
All Genders
18+
Years
Multiple Sites
An Investigation of Effectiveness and Safety of Varenicline Tartrate in Helping People Quit Smoking
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Multinational Study Of Efficacy And Safety Of Varenicline Tartrate For Smoking Cessation
To investigate safety and efficacy of varenicline tartrate in helping people quit smoking
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Smoking Cessation
  • Drug: Varenicline tartrate
  • Drug: Placebo
Not Provided
Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology. 2009 Apr;14(3):384-92. doi: 10.1111/j.1440-1843.2008.01476.x. Epub 2009 Feb 20.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
334
June 2007
Not Provided

Inclusion Criteria:

  • Current cigarette smokers between the ages of 18 and 75 years, who are motivated to stop smoking

Exclusion Criteria:

  • Patients currently suffering from depression, or have been diagnosed with depression in the last 12 months, or subjects with past or present history of psychosis, panic disorder, or bipolar disorder
  • Any subject with known severe chronic obstructive pulmonary disease (COPD)
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
China,   Singapore,   Thailand
 
 
NCT00371813
A3051055
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2015

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now